⌘K

07:03:07·504d

SECFilingvia Quantisnow

Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Leadership Update

ByQuantisnow·Wall Street's wire, on your screen.

GLUE· Monte Rosa Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

GLUE
Monte Rosa Therapeutics Inc.
Health Care

Recent analyst ratings

Dec 19UpdateWells Fargo$11.00
Feb 15UpdateWedbush$11.00
Jan 3UpdateWells Fargo$18.00
Oct 13UpdateUBS$22.00
Aug 15UpdateJefferies$20.00
Apr 28UpdateCredit Suisse$19.00

Related

SEC1d
SEC Form DEFA14A filed by Monte Rosa Therapeutics Inc.
SEC1d
SEC Form DEF 14A filed by Monte Rosa Therapeutics Inc.
PR11d
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
SEC14d
SEC Form 144 filed by Monte Rosa Therapeutics Inc.
INSIDER15d
SEC Form 4 filed by Warmuth Markus
INSIDER20d
SEC Form 4 filed by Nickson Philip
INSIDER23d
SEC Form 4 filed by Bowen Matthew
INSIDER23d
SEC Form 3 filed by new insider Bowen Matthew